Argenx – Patient Worthy

source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

Post author:Jessica Lynn
Post published:June 5, 2020
Post category:Chronic Inflammatory Demyelinating Polyneuropathy Idiopathic Thrombocytopenic Purpura Myasthenia Gravis Pemphigus and pemphigoid

According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More